Late-life GFAP (astrogliosis marker) was significantly associated with incident all-cause dementia, along with p-tau181 and NfL.

Clinical Score: 0.500 Price: $0.50 Alzheimer's disease human Status: extracted

What This Experiment Tests

Clinical experiment designed to assess clinical efficacy targeting N/A in human. Primary outcome: Late-life GFAP (astrogliosis marker) was significantly associated with incident all-cause dementia,

Description

GFAP = glial fibrillary acidic protein; all late-life plasma biomarkers showed significant associations with dementia risk

TARGET GENE
N/A
MODEL SYSTEM
human
ESTIMATED COST
$0
TIMELINE
0 months
PATHWAY
neuroinflammation
SOURCE
pmid_39068543
PRIMARY OUTCOME
Late-life GFAP (astrogliosis marker) was significantly associated with incident all-cause dementia, along with p-tau181 and NfL.

Scoring Dimensions

Info Gain 0.00 (25%) Feasibility 0.00 (20%) Hyp Coverage 0.00 (20%) Cost Effect. 0.00 (15%) Novelty 0.00 (10%) Ethical Safety 0.00 (10%) 0.500 composite

Related Hypotheses (1)

Age-related neuroinflammation mimics early Alzheimer's disease pathology0.362

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.